Search
-
ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018
Media
Juluca, the first 2-drug regimen, once daily, single pill regimen, maintains viral suppression through 100 weeks.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolutegravirrilpivirine-at-aids-2018/
First published: 24 July 2018
-
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV
Media
If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-new-drug-application-to-us-fda-for-the-first-monthly-injectable-two-drug-regimen-of-cabotegravir-and-rilpivirine-for-treatment-of-hiv/
First published: 29 April 2019
-
ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy
Media
ViiV announced the start of a phase III clinical trial for the safety and efficacy of dolutegravir&rilpivirine for adult patients with HIV.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-begins-phase-iii-programme-with-dolutegravirrilpivirine-combination-for-hiv-maintenance-therapy/
First published: 06 May 2015
-
Fresh insights could finally help us tackle RSV
Behind the science magazine
The 60 year search for solutions for RSV
https://www.gsk.com/en-gb/behind-the-science-magazine/fresh-insights-could-finally-help-us-tackle-rsv/
First published: 11 February 2022
-
ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
Media
ViiV Healthcare completed submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA).
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-new-drug-application-to-the-fda-for-fostemsavir-an-investigational-first-in-class-attachment-inhibitor-for-the-treatment-of-hiv-in-adults/
First published: 05 December 2019
-
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019
Media
Week 96 data from the BRIGHTE study of fostemsavir continue to show improvement in virologic suppression and immunologic response
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-96-week-data-from-phase-iii-study-of-investigational-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv-at-ias-2019/
First published: 22 July 2019
-
GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs
Media
GSK & Concert Pharmaceuticals to collaborate on deuterium-containing medicines, incl. CTP-518, a protease inhibitor for the treatment of HIV
https://www.gsk.com/en-gb/media/press-releases/gsk-and-concert-pharmaceuticals-form-alliance-to-develop-novel-deuterium-modified-drugs/
First published: 01 June 2009
-
ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1
Media
ViiV present 24-week interim results from Phase III SAILING study at the 20th Conference on Retroviruses and Opportunistic Infections (CROI)
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-data-from-phase-iii-study-of-dolutegravir-vs-raltegravir-in-treatment-experienced-adults-with-hiv-1/
First published: 06 March 2013
-
Millions of people living with chronic hepatitis B are unaware they have the virus. So why aren’t they getting diagnosed?
Behind the science magazine
Under-diagnosis of chronic hepatitis B is worrying healthcare professionals because it can lead to serious consequences over time.
https://www.gsk.com/en-gb/behind-the-science-magazine/chronic-hepatitis-b-stigma-discrimination-diagnosis/
First published: 06 November 2023
-
GSK announces results evaluating its investigational monoclonal antibody, otilimab, for the treatment of hospitalised adult patients with COVID-19
Media
GSK today announce results from the phase 2 proof of concept OSCAR study with otilimab, an investigational anti-GM-CSF monoclonal antibody.
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-otilimab-data-for-treatment-of-covid-19/
First published: 25 February 2021